Equipoise
Boldenone Undecylenate · EQ · Bold · Boldabol · Ganabol · Parenabol · Equigan
Last updated
At a glance
100
Testosterone = 100
50
Testosterone = 100
Overview
Equipoise — boldenone undecylenate, universally called EQ — is the compound people run when they want slow, dry, vascular mass that looks like it was earned. It's a testosterone analog with a single structural tweak (a Δ1,2 double bond on the A-ring) that cuts aromatization roughly in half and dials down androgenic pressure, while preserving full anabolic signaling. What you get is a compound that builds quality tissue without the bloat of test, without the mental sides of tren, and with a signature boost in red blood cell mass that shows up as cardio endurance, pumps that last into the next session, and the kind of vein-splitting vascularity EQ is famous for by week 12.
The community uses it three ways: as the backbone of a long lean bulk stacked with test, as a recomp / conditioning driver on maintenance calories (the appetite bump is a genuine feature), and as an endurance-forward add for hybrid athletes who want the erythropoietic tailwind. It's not a fast compound and it's not a short-cycle compound — run under 14 weeks it's essentially wasted money.
"EQ is one of those compounds where 12 weeks is really the bare minimum and anything less is a waste — users report peak effects between weeks 10–16, especially in terms of vascularity and fullness." — r/steroids community reference (2023)
The rest of this page covers what you actually need to run EQ well: dosing ladders for first-cycle through advanced users, cycle length and ester timing (including why PCT starts 5–6 weeks after your last pin, not two), stacks for bulking, cutting, and recomp, hematocrit management — the single most important thing to get right on EQ — side effect mitigation including the "EQ anxiety" phenomenon, and a full SERM-based PCT protocol for the long undecylenate ester.
How Equipoise works
Equipoise is 1-dehydrotestosterone — structurally identical to testosterone except for an added double bond between carbons 1 and 2 on the A-ring. That single modification changes how the molecule interacts with the androgen receptor, aromatase, and 5α-reductase, and it's the reason EQ behaves so differently from its parent hormone despite the near-identical structure.
Androgen Receptor Binding and the Δ1,2 Modification#
The 1,2-double bond shifts boldenone's receptor profile: moderately reduced androgenic activity with preserved anabolic signalling, yielding the commonly cited 100:50 anabolic:androgenic ratio relative to testosterone. In practical terms, users get testosterone-level nitrogen retention and protein synthesis at the muscle tissue level with proportionally less androgenic load on skin, scalp, and prostate.
"Boldenone is a synthetic anabolic-androgenic steroid derived from testosterone with a double bond between C1 and C2, which confers less androgenic and greater anabolic potency relative to testosterone." — Dirikolu L, Lehner AF, Journal of Veterinary Pharmacology and Therapeutics, 2023
Chronic supraphysiological exposure does downregulate AR mRNA expression in some tissues over time, which is part of why EQ cycles show diminishing returns past ~18 weeks even at high doses.
"Boldenone undecylenate treatment induced a significant down-regulation in androgen receptor mRNA expression and caused marked testicular oxidative damage." — Behairy A et al., Antioxidants (Basel), 2020
Erythropoiesis — EQ's Signature Effect#
This is what EQ is actually famous for. Boldenone drives a pronounced AR-mediated erythropoietic response: increased erythropoietin (EPO) output and suppressed hepcidin, expanding red blood cell mass and hematocrit more aggressively (per mg) than testosterone itself.
"Testosterone administration increased hemoglobin and hematocrit in a dose-dependent manner, an effect mediated by increased erythropoietin (EPO) and suppressed hepcidin." — Bachman E et al., Journal of Gerontology A Biological Sciences and Medical Sciences, 2014
The practical payoff: better oxygen delivery to working muscle, noticeable endurance bump, the vascular/full look EQ is prized for, and a genuine GPP boost that combat athletes and hybrid lifters chase. The practical cost: hematocrit creep. Most users at 500–600 mg/week hit Hct >54% by week 10 and need to donate blood to stay in range. This is the single most important thing to monitor on EQ — it's the dose-limiting side effect long before muscle-building plateaus.
Reduced Aromatization#
EQ aromatizes to estradiol at roughly half the rate of testosterone. The Δ1,2 modification makes it a poorer substrate for the aromatase enzyme, so equivalent mg doses produce meaningfully less E2.
This is why many users running EQ with a TRT-dose test base (200–300 mg/week) need little or no AI, and why water retention on EQ cycles is minimal compared to test-only or test/deca runs. The look is drier, harder, more vascular — not because EQ is "dry" per se, but because the estrogen ceiling on the cycle is lower.
It does not mean gyno is impossible — at 600+ mg/week with a high test base, E2 can still climb. Keep anastrozole on hand PRN rather than running it blind.
5α-Reductase Resistance and the Hair Question#
Because of the 1,2-double bond, boldenone is not efficiently reduced by 5α-reductase to a DHT analog the way testosterone is. Instead, its androgenic metabolites are closer to 1-testosterone-like compounds that retain direct AR activity without going through the DHT pathway.
The practical implication for hair-conscious users: finasteride and dutasteride do not meaningfully protect against EQ-driven hair loss. If you're MPB-predisposed and running EQ, the protection has to come from topical AR antagonists (RU58841, pyrilutamide) acting at the receptor level in scalp tissue, not from 5-AR inhibition upstream. The same logic applies to prostate and sebaceous tissue — EQ's androgenic load bypasses the 5-AR bottleneck.
Downstream Anabolic Signalling#
Once bound to the AR, the boldenone-AR complex translocates to the nucleus and drives the classical anabolic programme: increased nitrogen retention, muscle protein synthesis, IGF-1 expression in skeletal muscle, and satellite cell activation. Combined with the erythropoietic boost, this produces EQ's characteristic result — slow, steady, lean mass accrual with visibly improved vascularity and work capacity rather than the rapid scale weight and water seen on shorter-ester wet compounds.
The appetite increase most users report is a secondary but reliable effect — mechanistically less well-characterized, possibly ghrelin- or hypothalamic-mediated, but consistent enough across users that bodybuilders deliberately use EQ to eat through cuts or to push bulk calories without force-feeding.
"EQ is one of those compounds where 12 weeks is really the bare minimum and anything less is a waste—users report peak effects between weeks 10–16, especially in terms of vascularity and fullness." — r/steroids community reference, 2023
The slow onset isn't a pharmacodynamic quirk — it's the long undecylenate ester combined with the time needed for RBC mass expansion and cumulative AR-driven gene expression changes to show up at the tissue level. This is why EQ rewards patience and 16–20 week cycles and punishes anyone trying to run it like a 10-week test cycle.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 300–400 mg | Weekly | Documented entry-level range |
| Mid | 500–600 mg | Weekly | Most commonly studied range |
| High | 600–1000 mg | Weekly | Weekly or twice-weekly IM injection. Split dosing (e.g. Mon/Thu) keeps blood levels more stable but weekly is sufficient given the long ester. Some users frontload week 1 (e.g. 1200 mg) to reach saturation faster since EQ otherwise takes 4–6 weeks to kick in. |
Cycle length & outcomes
Documented cycle
16–20 weeks
Plateau after
18 wks
Cycle Length & Onset#
Equipoise is the most patient compound in the standard AAS toolkit. The undecylenate ester is long, steady-state takes 5–6 weeks of weekly dosing, and the visible payoff — fullness, vascularity, appetite, conditioning — shows up in the back half of the cycle. Anything shorter than 14 weeks and you're paying for an ester you never get to use.
"EQ is one of those compounds where 12 weeks is really the bare minimum and anything less is a waste—users report peak effects between weeks 10–16, especially in terms of vascularity and fullness." — r/steroids community reference (2023)
Pharmacokinetically this tracks: equine IM data puts absorption half-life at ~8.5 h and elimination half-life at ~5 days, with meaningful detection out to 5–6 months post-injection (Soma et al., J Vet Pharmacol Ther 2007). In humans the community consensus half-life runs 7–10 days.
Dose Ladder by Goal#
| Goal | Cycle Length | EQ Dose | Test Base |
|---|---|---|---|
| First EQ cycle / lean bulk | 16 weeks | 300–400 mg/week | 300 mg/week |
| Recomp / conditioning | 20 weeks | 400–500 mg/week | 150–200 mg/week (cruise) |
| Intermediate lean mass | 16–20 weeks | 500–600 mg/week | 300–500 mg/week |
| Advanced aesthetic blast | 18–20 weeks | 600–800 mg/week | 300–500 mg/week |
| Endurance / GPP-focused | 16 weeks | 300–400 mg/week | 150 mg/week (cruise) |
Diminishing returns set in above ~800 mg/week — hematocrit becomes the limiting factor long before muscle-building does. Most experienced users land around 500–600 mg/week and stay there cycle after cycle.
Frontloading vs. Slow-Start#
Because EQ takes 4–6 weeks to reach steady state, some users frontload week 1 with a double dose (e.g. 1200 mg split across two pins) to cut a couple weeks off the onset. This works — it doesn't change total exposure, just shifts the curve forward. The trade-off is you also hit hematocrit issues a couple weeks earlier, so move your first follow-up CBC to week 4–5 instead of week 6 if you frontload.
No taper is needed at the end of the cycle — the long ester tapers itself over 4–5 weeks after the last pin.
Injection Schedule#
Weekly is sufficient given the ester. Twice-weekly splits (Mon/Thu) give slightly smoother blood levels and pair cleanly with most test ester schedules — if you're already pinning Test E or Test C twice weekly, just add EQ to the same syringe. 200 mg/mL is the standard UGL concentration; 300 mg/mL brews exist but the higher solvent load often causes PIP and isn't worth the smaller shot volume.
Bloodwork Cadence#
This is non-negotiable on EQ. Testosterone-driven erythropoiesis is AR-mediated and dose-dependent, and EQ hits this pathway disproportionately hard per mg (Bachman et al., J Gerontol A Biol Sci Med Sci 2014).
| Timepoint | Panel | Why |
|---|---|---|
| Baseline (pre-cycle) | CBC, CMP, lipids, E2, total/free T | Establish your starting hematocrit floor |
| Week 6 | CBC, E2, lipids | Catch early hematocrit drift before symptoms |
| Week 12 | CBC, CMP, lipids, E2 | Mid-to-late cycle check — donate if Hct >52% |
| Week 18–20 (cycle end) | Full panel | Baseline for PCT planning |
| 6 weeks post-PCT | Full panel + HPTA (LH/FSH, T) | Confirm recovery |
Donate blood proactively at week 8 if you trend high at baseline. Don't wait for headaches, BP spikes, or tinnitus — by then you're already at 55%+.
PCT Timing#
The #1 EQ mistake is starting PCT on a test-ester timeline. Last pin to PCT start = 5–6 weeks for undecylenate, not the 2–3 weeks that works for Test E. Starting earlier means your SERMs are fighting active exogenous androgens and you waste the protocol.
Standard post-EQ PCT:
- Nolvadex 40/40/20/20 mg/day × 4 weeks
- Clomid 50/50/25/25 mg/day × 4 weeks (optional add if suppression was deep)
- Starting 5–6 weeks after the last EQ pin (and after test base has cleared — run the test ester timeline off your shortest-ester compound)
Or skip PCT entirely and drop to a TRT cruise (150–200 mg/week test) — which, given EQ's natural fit for long blast-and-cruise blocks, is what most experienced users end up doing.
Body Transformation Preview
Lean Mass Gain
9.8 lbs
7.3–12.2 lbs range
Fat Loss
1.4 lbs
1.0–1.7 lbs range
Lean Gain by Week
Risks & mistakes
Common (most users)#
- Elevated hematocrit / hemoglobin — the signature EQ effect. Expect Hct to climb 3–6 percentage points over a 16-week run at 500–600 mg/week. Mitigation: donate blood at week 8 (and again at week 14 if needed), keep cardio in the program, hydrate aggressively, and consider low-dose aspirin if cleared. Pull a CBC at baseline, week 6, and week 12 — non-negotiable.
"Testosterone administration increased hemoglobin and hematocrit in a dose-dependent manner, an effect mediated by increased erythropoietin (EPO) and suppressed hepcidin." — Bachman et al., J Gerontol A Biol Sci Med Sci (2014)
- Increased appetite — genuinely one of EQ's most reliable effects and a feature on a lean bulk. If you're running EQ on a cut, front-load meals with volume (veg, lean protein) so the hunger doesn't derail the deficit.
- Mild BP elevation — mostly secondary to hematocrit. Daily tadalafil 5 mg or telmisartan handles it cleanly. Cardio 3x/week also pulls numbers down meaningfully.
- Acne / oily skin — AR-driven, not DHT-driven on EQ since boldenone isn't a 5-AR substrate. Finasteride won't help. Topical adapalene + benzoyl peroxide, plus keeping the test base reasonable, is the fix.
- Injection volume fatigue — 500–600 mg/week at 200 mg/mL is 2.5–3 mL. Split into two pins (Mon/Thu) and rotate sites (glute, ventroglute, quad, delt).
Uncommon (dose-dependent or individual)#
- "EQ anxiety" / insomnia / racing thoughts — a well-known community phenomenon that hits a subset of users hard and leaves others completely untouched. Mechanism isn't well characterized. If it shows up in weeks 4–8, dose-reduce by 30% first; if it persists, drop the compound. Not worth fighting through — it doesn't adapt out.
- Estrogenic sides (water retention, nipple sensitivity, mild gyno) — EQ aromatizes at roughly half the rate of test, so at TRT-dose test base many run it without AI. If sides appear, add anastrozole 0.25 mg E3D and recheck E2 in 2 weeks. Don't crash estrogen — EQ users who over-AI end up with flat muscles and joint pain.
- Adverse lipid shifts — ↓HDL, ↑LDL is expected on any AAS run; EQ is middle-of-the-pack here. Citrus bergamot 1000 mg/day + 3–4 g EPA/DHA + cardio. Check a lipid panel at week 12 and adjust.
- MPB acceleration — boldenone isn't reduced to DHT, but it's still AR-active in scalp tissue. Topical antiandrogens (RU58841, pyrilutamide) are the move here; oral finasteride does comparatively little against EQ specifically.
- Testicular atrophy / libido drop — full HPTA suppression is guaranteed. A proper test base (200–300 mg/week minimum) handles libido. HCG 250–500 IU twice weekly throughout the cycle preserves testicular volume if that matters to you.
Rare but serious#
- Polycythemia with thrombotic risk — Hct >54% sustained is a real clotting risk. Warning signs: persistent headache, visual disturbance, dizziness on standing, unusual fatigue, facial plethora. Stop the cycle, donate blood, pull a CBC immediately.
- Cardiac remodeling / LVH — a long-run risk of any 16–20 week AAS cycle at supraphysiological doses. Keep Z2 cardio in the program, don't chase 1000 mg/week without a reason, and limit total blast time per year.
- Testicular oxidative damage — shown in animal models at supraphysiologic doses; clinical relevance in men running reasonable doses with HCG is likely low, but it's why HCG-on-cycle is a smart default on long EQ runs.
"Boldenone undecylenate treatment induced a significant down-regulation in androgen receptor mRNA expression and caused marked testicular oxidative damage." — Behairy et al., Antioxidants (2020)
- Depressive episodes post-cycle — more a PCT phenomenon than an on-cycle one, but worth naming. A clean SERM-based PCT started on time (week 5–6 after last pin) is the best prophylaxis.
Hard contraindications#
- Baseline hematocrit >52% or diagnosed polycythemia — EQ will push you into clinically dangerous territory within weeks.
- Untreated hypertension — get BP into normal range (with telmisartan, cialis, lifestyle, whatever it takes) before starting, not during.
- Dyslipidemia or existing cardiovascular disease — EQ will make it worse; stabilize lipids and cardiac status first.
- History of DVT, PE, stroke, MI, or any thromboembolic event — the erythrocytosis risk profile is incompatible with this history. Pick a different compound.
- Active malignancy — AAS are contraindicated; no exceptions.
- Tested athletic competition within 6 months — EQ metabolites are detectable for 5–6 months after the last injection. This is not a compound you can time around a test.
- Pregnancy or possibility of pregnancy — teratogenic; virilizes female fetuses.
Women, PCT, and long-ester timing#
Women: EQ is not recommended. The long undecylenate ester means that if virilization symptoms (voice deepening, clitoral enlargement, hirsutism) appear, they persist for weeks after the last injection — by the time you notice, you're already locked in. Women chasing similar conditioning effects use Primobolan or Anavar instead, where short-ester / oral kinetics allow immediate discontinuation if sides appear.
PCT timing is the #1 EQ mistake. Because the undecylenate ester has a ~5–7 day elimination half-life and active androgen persists for weeks after the last pin, PCT must start 5–6 weeks after the last injection — not the 2 weeks that works for test E. Starting too early means running SERMs against still-suppressive androgen levels and wasting the PCT.
"Boldenone undecylenate was rapidly absorbed from the injection site (absorption half-life = 8.5 h), and the elimination half-life of boldenone undecylenate was 123 h (5.1 days) after a single intramuscular dose." — Soma et al., J Vet Pharmacol Ther (2007)
Standard PCT: Nolvadex 40/40/20/20 mg + Clomid 50/50/25/25 mg, starting week 5–6 post-last-pin. Or skip PCT entirely and cruise on a TRT dose of test — which, for most people running 16–20 week EQ cycles, is the cleaner path.
Stack & combine
Multipliers applied when these compounds run together. Values > 1 indicate a bonus on that axis. Tap a partner to expand the mechanism.
| Partner | Type | Lean | Fat loss | Recovery |
|---|---|---|---|---|
| synergistic | ×1.08 | ×1.16 | ×1.10 | |
| synergistic | ×1.15 | ×1.05 | ×1.12 |
FAQ — Equipoise
Research & citations
5 studies cited on this page.
Conclusion
Equipoise (Boldenone Undecylenate) is the textbook long-ester injectable for slow, dry gains and unmatched vascularity, as long as you respect its need for patience and smart hematocrit management.
Key takeaways:
- Run 400–600 mg/week for 16–20 weeks — 12 weeks is too short to get the real EQ effect
- Always stack with at least 200 mg/week testosterone to maintain libido and androgenic tone
- IM injection only; split dosing (2x/week) is ideal but weekly is fine due to long half-life (7–10 days)
- Monitor hematocrit closely — blood donation is not optional at these doses
- Use an AI PRN, but EQ's aromatization is low enough that many get by with just a test base
- Start PCT with Nolvadex + Clomid 5–6 weeks after last shot (not 2 weeks like test E)
- Classic stack: Test + EQ + Anavar for dry mass with fullness, appetite, and summer-level vascularity
If you want steady, vein-popping lean gains without the bloat of higher-aromatizing AAS and you can commit to a long, patient run (and regular bloodwork), EQ is hard to beat for a seasoned user dialing in conditioning.